David Bianculli

But again, this is a very entrenched interest in the drug pricing arena, and it'll be hard to do.

But again, this is a very entrenched interest in the drug pricing arena, and it'll be hard to do.

But again, this is a very entrenched interest in the drug pricing arena, and it'll be hard to do.

Well, you know, the fact of the matter is, and there's been some studies about this, you know, industry funding of research is certainly important. But government funding has been just as important. You know, 300 and something drugs approved by the FDA in the last decade, all but two of them had some element of government funding in them.

Well, you know, the fact of the matter is, and there's been some studies about this, you know, industry funding of research is certainly important. But government funding has been just as important. You know, 300 and something drugs approved by the FDA in the last decade, all but two of them had some element of government funding in them.

Well, you know, the fact of the matter is, and there's been some studies about this, you know, industry funding of research is certainly important. But government funding has been just as important. You know, 300 and something drugs approved by the FDA in the last decade, all but two of them had some element of government funding in them.

So there are some studies out there suggesting that the industry estimates of what it costs them to bring a drug to market, what they spend on research and development have been inflated. And perhaps most damning, the House Oversight Committee did a study that found drug makers spend more on stock buybacks and investor dividends than they do on research and development.

So there are some studies out there suggesting that the industry estimates of what it costs them to bring a drug to market, what they spend on research and development have been inflated. And perhaps most damning, the House Oversight Committee did a study that found drug makers spend more on stock buybacks and investor dividends than they do on research and development.

So there are some studies out there suggesting that the industry estimates of what it costs them to bring a drug to market, what they spend on research and development have been inflated. And perhaps most damning, the House Oversight Committee did a study that found drug makers spend more on stock buybacks and investor dividends than they do on research and development.

So the doctors in Arkansas didn't get anything, at least the ones I've spoken to. You know, there was no financial benefit to them from this discovery. And, you know, the ones I talked to said they really weren't looking for that. They were just incredibly gratified to find something that was going to help patients. You know, it was incredible.

So the doctors in Arkansas didn't get anything, at least the ones I've spoken to. You know, there was no financial benefit to them from this discovery. And, you know, the ones I talked to said they really weren't looking for that. They were just incredibly gratified to find something that was going to help patients. You know, it was incredible.

So the doctors in Arkansas didn't get anything, at least the ones I've spoken to. You know, there was no financial benefit to them from this discovery. And, you know, the ones I talked to said they really weren't looking for that. They were just incredibly gratified to find something that was going to help patients. You know, it was incredible.

It was a pretty grim period where, you know, they want to help patients. They want to get them better, give them an extension of life. And it was really hard to do before this discovery. The Boston doctors who were researching this drug, they didn't directly get something, but their institution did. They get royalties from Revlimid.

It was a pretty grim period where, you know, they want to help patients. They want to get them better, give them an extension of life. And it was really hard to do before this discovery. The Boston doctors who were researching this drug, they didn't directly get something, but their institution did. They get royalties from Revlimid.

It was a pretty grim period where, you know, they want to help patients. They want to get them better, give them an extension of life. And it was really hard to do before this discovery. The Boston doctors who were researching this drug, they didn't directly get something, but their institution did. They get royalties from Revlimid.

So there is a little bit of a benefit there to the research institution.

So there is a little bit of a benefit there to the research institution.

So there is a little bit of a benefit there to the research institution.

Yeah, I think usually that's the case. And, you know, a lot of the most important developments have come out of academic labs, hospital labs. And, you know, these labs are willing to take chances that often pharmaceutical companies aren't. You know, they will study things that a drug company might look at and say, oh, there's not a big enough market or we're not sure that this will work.

Yeah, I think usually that's the case. And, you know, a lot of the most important developments have come out of academic labs, hospital labs. And, you know, these labs are willing to take chances that often pharmaceutical companies aren't. You know, they will study things that a drug company might look at and say, oh, there's not a big enough market or we're not sure that this will work.